Acute renal failure, COVID-19 and deaths, worrying rates in intensive care units: a cross-sectional study.

IF 1.3 4区医学 Q2 MEDICINE, GENERAL & INTERNAL Sao Paulo Medical Journal Pub Date : 2024-08-09 eCollection Date: 2024-01-01 DOI:10.1590/1516-3180.2023.0150.R1.13052024

Yoshimi José Ávila Watanabe, Lívia Maria Rezende Carvalho, João Victor Marques Guedes, André Oliveira Baldoni, Vinícius Silva Belo, Alba Otoni

{"title":"Acute renal failure, COVID-19 and deaths, worrying rates in intensive care units: a cross-sectional study.","authors":"Yoshimi José Ávila Watanabe, Lívia Maria Rezende Carvalho, João Victor Marques Guedes, André Oliveira Baldoni, Vinícius Silva Belo, Alba Otoni","doi":"10.1590/1516-3180.2023.0150.R1.13052024","DOIUrl":null,"url":null,"abstract":"Background: Acute kidney failure is a serious consequence of coronavirus disease 2019 (COVID-19).Objectives: To identify the prevalence of COVID-19, kidney failure, frequency of death, and associated factors in patients receiving intensive care.Design and setting: Analytical cross-sectional study conducted in the intensive care unit (ICU) of a medium-sized philanthropic general hospital in center-west Minas Gerais.Methods: Adults and older individuals who underwent real-time polymerase chain reaction testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were evaluated by the nephrology team.Results: Among the 176 patients, the prevalence of COVID-19 and acute kidney injury (AKI) were 103 (58.5%) and 132 (75%), respectively, and 44 (25%) had chronic kidney disease (CKD) and 16 (15,5%) were positive for SARS-CoV-2. In the Charlson index classification, which estimates the risk of death, a statistically significant difference was identified in the percentages of groups with and without COVID-19 for indices 0, 1, and 2. There was a significant association between kidney disease and ICU mortality (P < 0.05). Patients with CKD had fewer fatal outcomes (13/97, 13.4%) than those with AKI (85/97, 87.6%).Conclusions: COVID-19 rates remained high long after diagnosis and prevention of SARS-CoV-2 infection. In addition, a higher death rate among patients who developed AKI, whose prevalence was also greater than that in the national literature, regardless of the presence of COVID-19, revealed a worrying scenario and corroborated the need for early and judicious approaches to preserve the lives of patients with AKI admitted to intensive care units.","PeriodicalId":49574,"journal":{"name":"Sao Paulo Medical Journal","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11329267/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sao Paulo Medical Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1590/1516-3180.2023.0150.R1.13052024","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Acute kidney failure is a serious consequence of coronavirus disease 2019 (COVID-19).

Objectives: To identify the prevalence of COVID-19, kidney failure, frequency of death, and associated factors in patients receiving intensive care.

Design and setting: Analytical cross-sectional study conducted in the intensive care unit (ICU) of a medium-sized philanthropic general hospital in center-west Minas Gerais.

Methods: Adults and older individuals who underwent real-time polymerase chain reaction testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were evaluated by the nephrology team.

Results: Among the 176 patients, the prevalence of COVID-19 and acute kidney injury (AKI) were 103 (58.5%) and 132 (75%), respectively, and 44 (25%) had chronic kidney disease (CKD) and 16 (15,5%) were positive for SARS-CoV-2. In the Charlson index classification, which estimates the risk of death, a statistically significant difference was identified in the percentages of groups with and without COVID-19 for indices 0, 1, and 2. There was a significant association between kidney disease and ICU mortality (P < 0.05). Patients with CKD had fewer fatal outcomes (13/97, 13.4%) than those with AKI (85/97, 87.6%).

Conclusions: COVID-19 rates remained high long after diagnosis and prevention of SARS-CoV-2 infection. In addition, a higher death rate among patients who developed AKI, whose prevalence was also greater than that in the national literature, regardless of the presence of COVID-19, revealed a worrying scenario and corroborated the need for early and judicious approaches to preserve the lives of patients with AKI admitted to intensive care units.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

急性肾功能衰竭、COVID-19 和死亡、重症监护病房的担忧率：一项横断面研究。

背景：急性肾衰竭是冠状病毒病 2019（COVID-19）的严重后果：急性肾衰竭是冠状病毒病2019（COVID-19）的一个严重后果：确定接受重症监护的患者中COVID-19的流行率、肾衰竭、死亡频率及相关因素：在米纳斯吉拉斯州中西部一家中型慈善综合医院的重症监护室（ICU）进行横断面分析研究：方法：肾脏病小组对接受严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）实时聚合酶链反应检测的成人和老年人进行评估：在 176 名患者中，COVID-19 和急性肾损伤（AKI）的发病率分别为 103 人（58.5%）和 132 人（75%），44 人（25%）患有慢性肾病（CKD），16 人（15.5%）SARS-CoV-2 阳性。在估算死亡风险的夏尔森指数分类中，发现在指数 0、1 和 2 中，有 COVID-19 和没有 COVID-19 的组别百分比有显著的统计学差异。肾脏疾病与重症监护病房死亡率之间存在明显关联（P < 0.05）。与有 AKI 的患者（85/97，87.6%）相比，有 CKD 的患者死亡人数较少（13/97，13.4%）：结论：在确诊和预防 SARS-CoV-2 感染后很长时间内，COVID-19 的发病率仍然很高。结论：在诊断和预防 SARS-CoV-2 感染后很长时间内，COVID-19 的发病率仍然很高。此外，无论是否存在 COVID-19，发生 AKI 的患者的死亡率都高于国内文献报道的水平，这表明情况令人担忧，需要尽早采取明智的方法来挽救重症监护病房 AKI 患者的生命。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Sao Paulo Medical Journal 医学-医学：内科

CiteScore

2.20

自引率

7.10%

发文量

210

审稿时长

6-12 weeks

期刊介绍： Published bimonthly by the Associação Paulista de Medicina, the journal accepts articles in the fields of clinical health science (internal medicine, gynecology and obstetrics, mental health, surgery, pediatrics and public health). Articles will be accepted in the form of original articles (clinical trials, cohort, case-control, prevalence, incidence, accuracy and cost-effectiveness studies and systematic reviews with or without meta-analysis), narrative reviews of the literature, case reports, short communications and letters to the editor. Papers with a commercial objective will not be accepted.